Preclinical Development of novel therapeutic approaches in models resistant to targeted therapies in HER2-positive mammary breast cancer

Giusti, Veronica (2019) Preclinical Development of novel therapeutic approaches in models resistant to targeted therapies in HER2-positive mammary breast cancer, [Dissertation thesis], Alma Mater Studiorum Università di Bologna. Dottorato di ricerca in Oncologia, ematologia e patologia, 31 Ciclo. DOI 10.6092/unibo/amsdottorato/8849.
Documenti full-text disponibili:
[img] Documento PDF (English) - Richiede un lettore di PDF come Xpdf o Adobe Acrobat Reader
Disponibile con Licenza: Salvo eventuali più ampie autorizzazioni dell'autore, la tesi può essere liberamente consultata e può essere effettuato il salvataggio e la stampa di una copia per fini strettamente personali di studio, di ricerca e di insegnamento, con espresso divieto di qualunque utilizzo direttamente o indirettamente commerciale. Ogni altro diritto sul materiale è riservato.
Download (11MB)


HER2 enriched mammary breast cancer represents 15-25% of mammary carcinomas and is associated to increased aggressiveness and worse prognosis. Advent of targeted therapies against HER2 has improved 5-year survival up to 75%, nevertheless receptor discordance, which is observed in 10.8% of metastasis, as well as resistance to targeted therapies render it a still challenging disease. On the one hand, taking advange of a recently estabilished murine model of spontaneous loss of HER2 expression, we sought to understand the underlying mechanism, to evaluate role of trastuzumab and to identify identify druggable targets in HER2-negative metastasis or relapses of HER2-positive tumors. The study of transcriptome of cell lines with different HER2 expression has permitted us to identify pathways related to the modulation of this more malignant phenotype, which appeared to be promoted by trastuzumab. Some indications emerged for inhibition of PDGFR-B by sunitinib in tumours which have lost HER2 expression. On the other hand, a recently established collection of patient derived xenografts (PDX) was used to obtain models of progression where to evaluate the effect of neratinib, a pan-HER tyrosine kinase inhibitor. No abrupt loss of HER2 expression was registered in these models. Collectively, our data, obtained in ER-/PR- HER2+ PDX, strongly indicate a great and long-lasting efficacy of neratinib even in trastuzumab-resistance and after progression and call for further evaluation of neratinib in advanced clinical settings. In our PDX diagnosed as luminal B expressing HER2 (score 2+), neratinib alone had no effect but synergized with tamoxifen and their combination tended to confer a little survival benefit in vivo, thus underscoring the possible relevance of dual blockade in tumors expressing both hormone receptors and HER2.

Tipologia del documento
Tesi di dottorato
Giusti, Veronica
Dottorato di ricerca
Settore disciplinare
Settore concorsuale
Parole chiave
HER2, receptor discordance, breast cancer, PDGFR-B, sunitinib, RNASequencing, murine model, HER2 loss, trastuzumab, patient derived xenograft, neratinib, progression, luminal-B HER2 positive
Data di discussione
12 Aprile 2019

Altri metadati

Statistica sui download

Gestione del documento: Visualizza la tesi